Bronchopulmonary disposition of IV cefepime/taniborbactam (2-0.5 g) administered over 2 h in healthy adult subjects.
Tomefa E AsempaJoseph L KutiJeffrey C NascimentoSamuel J PopeEdward L SalernoPatrick J TroyYasmeen AbouelhassanPublished in: The Journal of antimicrobial chemotherapy (2023)
The observed bronchopulmonary exposures of taniborbactam and cefepime can be employed to design optimal dosing regimens for clinical trials in patients with pneumonia.